Tabula Rasa HealthCare, Inc.
Tabula Rasa HealthCare, Inc. TRHC Peers
See (TRHC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TRHC | $10.50 | +0.86% | 284M | -4.27 | -$2.46 | N/A |
| VEEV | $274.04 | -3.63% | 46B | 59.96 | $4.70 | N/A |
| GEHC | $75.16 | -0.46% | 35B | 16.07 | $4.76 | +0.17% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.17% |
| DOCS | $60.29 | -4.70% | 11.3B | 54.18 | $1.11 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $95.07 | -4.91% | 8.4B | 70.91 | $1.37 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSGU | $73.18 | -3.46% | 3.7B | N/A | N/A | N/A |
| BTSG | $20.46 | -4.36% | 3.7B | 77.26 | $0.27 | N/A |
Stock Comparison
TRHC vs VEEV Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, VEEV has a market cap of 46B. Regarding current trading prices, TRHC is priced at $10.50, while VEEV trades at $274.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas VEEV's P/E ratio is 59.96. In terms of profitability, TRHC's ROE is +121.31%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, TRHC is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs GEHC Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, GEHC has a market cap of 35B. Regarding current trading prices, TRHC is priced at $10.50, while GEHC trades at $75.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas GEHC's P/E ratio is 16.07. In terms of profitability, TRHC's ROE is +121.31%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, TRHC is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs GEHCV Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, TRHC is priced at $10.50, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas GEHCV's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, TRHC is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs DOCS Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, DOCS has a market cap of 11.3B. Regarding current trading prices, TRHC is priced at $10.50, while DOCS trades at $60.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas DOCS's P/E ratio is 54.18. In terms of profitability, TRHC's ROE is +121.31%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, TRHC is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SGFY Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, TRHC is priced at $10.50, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SGFY's P/E ratio is 70.91. In terms of profitability, TRHC's ROE is +121.31%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, TRHC is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs HQY Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, HQY has a market cap of 8.4B. Regarding current trading prices, TRHC is priced at $10.50, while HQY trades at $95.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas HQY's P/E ratio is 70.91. In terms of profitability, TRHC's ROE is +121.31%, compared to HQY's ROE of +0.06%. Regarding short-term risk, TRHC is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs RCM Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, TRHC is priced at $10.50, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas RCM's P/E ratio is -102.21. In terms of profitability, TRHC's ROE is +121.31%, compared to RCM's ROE of -0.02%. Regarding short-term risk, TRHC is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs BTSGU Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, BTSGU has a market cap of 3.7B. Regarding current trading prices, TRHC is priced at $10.50, while BTSGU trades at $73.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas BTSGU's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, TRHC is less volatile compared to BTSGU. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs BTSG Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, BTSG has a market cap of 3.7B. Regarding current trading prices, TRHC is priced at $10.50, while BTSG trades at $20.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas BTSG's P/E ratio is 77.26. In terms of profitability, TRHC's ROE is +121.31%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, TRHC is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs ONEM Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, TRHC is priced at $10.50, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ONEM's P/E ratio is -7.77. In terms of profitability, TRHC's ROE is +121.31%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, TRHC is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs PRVA Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, TRHC is priced at $10.50, while PRVA trades at $20.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas PRVA's P/E ratio is 175.82. In terms of profitability, TRHC's ROE is +121.31%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, TRHC is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs WGS Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, WGS has a market cap of 2.5B. Regarding current trading prices, TRHC is priced at $10.50, while WGS trades at $82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas WGS's P/E ratio is -62.42. In terms of profitability, TRHC's ROE is +121.31%, compared to WGS's ROE of -0.17%. Regarding short-term risk, TRHC is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs PGNY Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, TRHC is priced at $10.50, while PGNY trades at $23.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas PGNY's P/E ratio is 41.44. In terms of profitability, TRHC's ROE is +121.31%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, TRHC is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs CERT Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CERT has a market cap of 1.9B. Regarding current trading prices, TRHC is priced at $10.50, while CERT trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CERT's P/E ratio is -575.25. In terms of profitability, TRHC's ROE is +121.31%, compared to CERT's ROE of -0.00%. Regarding short-term risk, TRHC is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs PINC Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, PINC has a market cap of 1.8B. Regarding current trading prices, TRHC is priced at $10.50, while PINC trades at $21.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas PINC's P/E ratio is 21.05. In terms of profitability, TRHC's ROE is +121.31%, compared to PINC's ROE of +0.03%. Regarding short-term risk, TRHC is less volatile compared to PINC. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs GDRX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, GDRX has a market cap of 1.8B. Regarding current trading prices, TRHC is priced at $10.50, while GDRX trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas GDRX's P/E ratio is 70.00. In terms of profitability, TRHC's ROE is +121.31%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, TRHC is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs PHR Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, PHR has a market cap of 1.7B. Regarding current trading prices, TRHC is priced at $10.50, while PHR trades at $26.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas PHR's P/E ratio is -38.74. In terms of profitability, TRHC's ROE is +121.31%, compared to PHR's ROE of -0.16%. Regarding short-term risk, TRHC is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs NXGN Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, TRHC is priced at $10.50, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas NXGN's P/E ratio is -266.00. In terms of profitability, TRHC's ROE is +121.31%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, TRHC is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs SDGR Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SDGR has a market cap of 1.6B. Regarding current trading prices, TRHC is priced at $10.50, while SDGR trades at $21.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SDGR's P/E ratio is -8.24. In terms of profitability, TRHC's ROE is +121.31%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, TRHC is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs TXG Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, TXG has a market cap of 1.6B. Regarding current trading prices, TRHC is priced at $10.50, while TXG trades at $12.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas TXG's P/E ratio is -9.86. In terms of profitability, TRHC's ROE is +121.31%, compared to TXG's ROE of -0.22%. Regarding short-term risk, TRHC is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs TDOC Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, TDOC has a market cap of 1.5B. Regarding current trading prices, TRHC is priced at $10.50, while TDOC trades at $8.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas TDOC's P/E ratio is -1.49. In terms of profitability, TRHC's ROE is +121.31%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, TRHC is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs OMCL Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, OMCL has a market cap of 1.4B. Regarding current trading prices, TRHC is priced at $10.50, while OMCL trades at $28.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas OMCL's P/E ratio is 64.72. In terms of profitability, TRHC's ROE is +121.31%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, TRHC is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs AGTI Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, TRHC is priced at $10.50, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas AGTI's P/E ratio is -71.79. In terms of profitability, TRHC's ROE is +121.31%, compared to AGTI's ROE of -0.01%. Regarding short-term risk, TRHC is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs EVH Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, EVH has a market cap of 1.3B. Regarding current trading prices, TRHC is priced at $10.50, while EVH trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas EVH's P/E ratio is -9.14. In terms of profitability, TRHC's ROE is +121.31%, compared to EVH's ROE of -0.11%. Regarding short-term risk, TRHC is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs HSTM Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, HSTM has a market cap of 830M. Regarding current trading prices, TRHC is priced at $10.50, while HSTM trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas HSTM's P/E ratio is 43.16. In terms of profitability, TRHC's ROE is +121.31%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, TRHC is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs CTEV Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CTEV has a market cap of 782.5M. Regarding current trading prices, TRHC is priced at $10.50, while CTEV trades at $46.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CTEV's P/E ratio is -0.65. In terms of profitability, TRHC's ROE is +121.31%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, TRHC is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs NUTX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, NUTX has a market cap of 652.4M. Regarding current trading prices, TRHC is priced at $10.50, while NUTX trades at $115.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas NUTX's P/E ratio is 9.51. In terms of profitability, TRHC's ROE is +121.31%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, TRHC is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs MPLN-WT Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, TRHC is priced at $10.50, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, TRHC is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs ACCD Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, TRHC is priced at $10.50, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ACCD's P/E ratio is -3.08. In terms of profitability, TRHC's ROE is +121.31%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, TRHC is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs SHCR Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, TRHC is priced at $10.50, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SHCR's P/E ratio is -3.76. In terms of profitability, TRHC's ROE is +121.31%, compared to SHCR's ROE of -0.24%. Regarding short-term risk, TRHC is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs SY Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SY has a market cap of 499M. Regarding current trading prices, TRHC is priced at $10.50, while SY trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SY's P/E ratio is -4.73. In terms of profitability, TRHC's ROE is +121.31%, compared to SY's ROE of -0.28%. Regarding short-term risk, TRHC is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs DH Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, DH has a market cap of 449.8M. Regarding current trading prices, TRHC is priced at $10.50, while DH trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas DH's P/E ratio is -0.95. In terms of profitability, TRHC's ROE is +121.31%, compared to DH's ROE of -1.07%. Regarding short-term risk, TRHC is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SLGC Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, TRHC is priced at $10.50, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SLGC's P/E ratio is -3.04. In terms of profitability, TRHC's ROE is +121.31%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, TRHC is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SLGCW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, TRHC is priced at $10.50, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, TRHC's ROE is +121.31%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, TRHC is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs MPLN Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, TRHC is priced at $10.50, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MPLN's P/E ratio is -0.23. In terms of profitability, TRHC's ROE is +121.31%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, TRHC is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs NRC Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, NRC has a market cap of 369.8M. Regarding current trading prices, TRHC is priced at $10.50, while NRC trades at $15.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas NRC's P/E ratio is 15.91. In terms of profitability, TRHC's ROE is +121.31%, compared to NRC's ROE of +0.71%. Regarding short-term risk, TRHC is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SPOK Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SPOK has a market cap of 368.1M. Regarding current trading prices, TRHC is priced at $10.50, while SPOK trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SPOK's P/E ratio is 23.24. In terms of profitability, TRHC's ROE is +121.31%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, TRHC is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SLP Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SLP has a market cap of 353.4M. Regarding current trading prices, TRHC is priced at $10.50, while SLP trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SLP's P/E ratio is 48.81. In terms of profitability, TRHC's ROE is +121.31%, compared to SLP's ROE of +0.04%. Regarding short-term risk, TRHC is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs TBRG Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, TBRG has a market cap of 344.9M. Regarding current trading prices, TRHC is priced at $10.50, while TBRG trades at $22.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas TBRG's P/E ratio is -18.52. In terms of profitability, TRHC's ROE is +121.31%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, TRHC is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs HCAT Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, HCAT has a market cap of 277.4M. Regarding current trading prices, TRHC is priced at $10.50, while HCAT trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas HCAT's P/E ratio is -3.47. In terms of profitability, TRHC's ROE is +121.31%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, TRHC is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SOPH Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SOPH has a market cap of 249.9M. Regarding current trading prices, TRHC is priced at $10.50, while SOPH trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SOPH's P/E ratio is -3.74. In terms of profitability, TRHC's ROE is +121.31%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, TRHC is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SMFR Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, TRHC is priced at $10.50, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SMFR's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, TRHC is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs OPRX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, OPRX has a market cap of 245.8M. Regarding current trading prices, TRHC is priced at $10.50, while OPRX trades at $12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas OPRX's P/E ratio is -15.82. In terms of profitability, TRHC's ROE is +121.31%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, TRHC is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs CPSI Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, TRHC is priced at $10.50, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CPSI's P/E ratio is -183.80. In terms of profitability, TRHC's ROE is +121.31%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, TRHC is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs AMWL Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, AMWL has a market cap of 132.8M. Regarding current trading prices, TRHC is priced at $10.50, while AMWL trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas AMWL's P/E ratio is -0.83. In terms of profitability, TRHC's ROE is +121.31%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, TRHC is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs EUDA Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, EUDA has a market cap of 120M. Regarding current trading prices, TRHC is priced at $10.50, while EUDA trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas EUDA's P/E ratio is -5.98. In terms of profitability, TRHC's ROE is +121.31%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, TRHC is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs AUGX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, TRHC is priced at $10.50, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas AUGX's P/E ratio is -4.99. In terms of profitability, TRHC's ROE is +121.31%, compared to AUGX's ROE of -1.13%. Regarding short-term risk, TRHC is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs CCLD Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CCLD has a market cap of 102.8M. Regarding current trading prices, TRHC is priced at $10.50, while CCLD trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CCLD's P/E ratio is -11.05. In terms of profitability, TRHC's ROE is +121.31%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, TRHC is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs CCLDO Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CCLDO has a market cap of 100.8M. Regarding current trading prices, TRHC is priced at $10.50, while CCLDO trades at $19.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CCLDO's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, TRHC is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs FORA Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, FORA has a market cap of 64.3M. Regarding current trading prices, TRHC is priced at $10.50, while FORA trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas FORA's P/E ratio is -17.17. In terms of profitability, TRHC's ROE is +121.31%, compared to FORA's ROE of -0.13%. Regarding short-term risk, TRHC is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs CCLDP Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, TRHC is priced at $10.50, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CCLDP's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, TRHC is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs BEAT Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, BEAT has a market cap of 42.6M. Regarding current trading prices, TRHC is priced at $10.50, while BEAT trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas BEAT's P/E ratio is -1.70. In terms of profitability, TRHC's ROE is +121.31%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, TRHC is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs BEATW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, BEATW has a market cap of 35.2M. Regarding current trading prices, TRHC is priced at $10.50, while BEATW trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas BEATW's P/E ratio is -0.51. In terms of profitability, TRHC's ROE is +121.31%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, TRHC is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SNCE Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, TRHC is priced at $10.50, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SNCE's P/E ratio is -0.27. In terms of profitability, TRHC's ROE is +121.31%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, TRHC is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs AKLI Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, TRHC is priced at $10.50, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas AKLI's P/E ratio is -0.71. In terms of profitability, TRHC's ROE is +121.31%, compared to AKLI's ROE of -0.38%. Regarding short-term risk, TRHC is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs SHLT Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, TRHC is priced at $10.50, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SHLT's P/E ratio is -3.87. In terms of profitability, TRHC's ROE is +121.31%, compared to SHLT's ROE of -0.07%. Regarding short-term risk, TRHC is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs SHCRW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, TRHC is priced at $10.50, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, TRHC's ROE is +121.31%, compared to SHCRW's ROE of -0.24%. Regarding short-term risk, TRHC is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs STRM Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, STRM has a market cap of 22.7M. Regarding current trading prices, TRHC is priced at $10.50, while STRM trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas STRM's P/E ratio is -2.35. In terms of profitability, TRHC's ROE is +121.31%, compared to STRM's ROE of -0.68%. Regarding short-term risk, TRHC is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs RNLX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, TRHC is priced at $10.50, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas RNLX's P/E ratio is -0.33. In terms of profitability, TRHC's ROE is +121.31%, compared to RNLX's ROE of +1.94%. Regarding short-term risk, TRHC is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs LIFW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, TRHC is priced at $10.50, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas LIFW's P/E ratio is -0.02. In terms of profitability, TRHC's ROE is +121.31%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, TRHC is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs VSEEW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, VSEEW has a market cap of 21.4M. Regarding current trading prices, TRHC is priced at $10.50, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas VSEEW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, TRHC is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs SCNX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, SCNX has a market cap of 21.3M. Regarding current trading prices, TRHC is priced at $10.50, while SCNX trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas SCNX's P/E ratio is 2.46. In terms of profitability, TRHC's ROE is +121.31%, compared to SCNX's ROE of -0.24%. Regarding short-term risk, TRHC is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs ONMD Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ONMD has a market cap of 19.3M. Regarding current trading prices, TRHC is priced at $10.50, while ONMD trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ONMD's P/E ratio is -1.80. In terms of profitability, TRHC's ROE is +121.31%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, TRHC is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs VSEE Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, VSEE has a market cap of 19M. Regarding current trading prices, TRHC is priced at $10.50, while VSEE trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas VSEE's P/E ratio is -13.44. In terms of profitability, TRHC's ROE is +121.31%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, TRHC is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs MGRX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MGRX has a market cap of 17.5M. Regarding current trading prices, TRHC is priced at $10.50, while MGRX trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MGRX's P/E ratio is -0.35. In terms of profitability, TRHC's ROE is +121.31%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, TRHC is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs BFRGW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, BFRGW has a market cap of 16.7M. Regarding current trading prices, TRHC is priced at $10.50, while BFRGW trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas BFRGW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to BFRGW's ROE of -1.63%. Regarding short-term risk, TRHC is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs BFRG Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, BFRG has a market cap of 14.3M. Regarding current trading prices, TRHC is priced at $10.50, while BFRG trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas BFRG's P/E ratio is -1.89. In terms of profitability, TRHC's ROE is +121.31%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, TRHC is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs BBLN Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, TRHC is priced at $10.50, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas BBLN's P/E ratio is -0.04. In terms of profitability, TRHC's ROE is +121.31%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, TRHC is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs INOV Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, INOV has a market cap of 12.8M. Regarding current trading prices, TRHC is priced at $10.50, while INOV trades at $32.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas INOV's P/E ratio is 16.51. In terms of profitability, TRHC's ROE is +121.31%, compared to INOV's ROE of +0.03%. Regarding short-term risk, TRHC is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs ETAO Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, TRHC is priced at $10.50, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ETAO's P/E ratio is -0.01. In terms of profitability, TRHC's ROE is +121.31%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, TRHC is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs HCTI Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, HCTI has a market cap of 9.7M. Regarding current trading prices, TRHC is priced at $10.50, while HCTI trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas HCTI's P/E ratio is -0.03. In terms of profitability, TRHC's ROE is +121.31%, compared to HCTI's ROE of -23.25%. Regarding short-term risk, TRHC is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs MSPR Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MSPR has a market cap of 8.8M. Regarding current trading prices, TRHC is priced at $10.50, while MSPR trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MSPR's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, TRHC is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs HLTH Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, TRHC is priced at $10.50, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas HLTH's P/E ratio is -0.02. In terms of profitability, TRHC's ROE is +121.31%, compared to HLTH's ROE of -0.88%. Regarding short-term risk, TRHC is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs ZCMD Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ZCMD has a market cap of 6M. Regarding current trading prices, TRHC is priced at $10.50, while ZCMD trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ZCMD's P/E ratio is -9.59. In terms of profitability, TRHC's ROE is +121.31%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, TRHC is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs UPH Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, TRHC is priced at $10.50, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas UPH's P/E ratio is -0.07. In terms of profitability, TRHC's ROE is +121.31%, compared to UPH's ROE of -1.05%. Regarding short-term risk, TRHC is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs FOXO Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, FOXO has a market cap of 4.9M. Regarding current trading prices, TRHC is priced at $10.50, while FOXO trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas FOXO's P/E ratio is -0.02. In terms of profitability, TRHC's ROE is +121.31%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, TRHC is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs ACON Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ACON has a market cap of 4.3M. Regarding current trading prices, TRHC is priced at $10.50, while ACON trades at $7.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ACON's P/E ratio is -0.64. In terms of profitability, TRHC's ROE is +121.31%, compared to ACON's ROE of -1.27%. Regarding short-term risk, TRHC is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs PEARW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, TRHC is priced at $10.50, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas PEARW's P/E ratio is -0.00. In terms of profitability, TRHC's ROE is +121.31%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, TRHC is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs PEAR Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, TRHC is priced at $10.50, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas PEAR's P/E ratio is -0.08. In terms of profitability, TRHC's ROE is +121.31%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, TRHC is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs EUDAW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, EUDAW has a market cap of 3.8M. Regarding current trading prices, TRHC is priced at $10.50, while EUDAW trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas EUDAW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, TRHC is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs OTRK Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, OTRK has a market cap of 1.8M. Regarding current trading prices, TRHC is priced at $10.50, while OTRK trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas OTRK's P/E ratio is -0.03. In terms of profitability, TRHC's ROE is +121.31%, compared to OTRK's ROE of -2.70%. Regarding short-term risk, TRHC is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs WGSWW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, WGSWW has a market cap of 1.7M. Regarding current trading prices, TRHC is priced at $10.50, while WGSWW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas WGSWW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, TRHC is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs CMAX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, TRHC is priced at $10.50, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CMAX's P/E ratio is -0.00. In terms of profitability, TRHC's ROE is +121.31%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, TRHC is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs WORX Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, WORX has a market cap of 1.6M. Regarding current trading prices, TRHC is priced at $10.50, while WORX trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas WORX's P/E ratio is -0.49. In terms of profitability, TRHC's ROE is +121.31%, compared to WORX's ROE of -0.32%. Regarding short-term risk, TRHC is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs LIFWZ Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, TRHC is priced at $10.50, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, TRHC is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs OTRKP Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, OTRKP has a market cap of 1.1M. Regarding current trading prices, TRHC is priced at $10.50, while OTRKP trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, TRHC's ROE is +121.31%, compared to OTRKP's ROE of -2.70%. Regarding short-term risk, TRHC is more volatile compared to OTRKP. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs ICCT Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ICCT has a market cap of 731.6K. Regarding current trading prices, TRHC is priced at $10.50, while ICCT trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ICCT's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to ICCT's ROE of +20.01%. Regarding short-term risk, TRHC is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs KERNW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, TRHC is priced at $10.50, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas KERNW's P/E ratio is -0.00. In terms of profitability, TRHC's ROE is +121.31%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, TRHC is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs KERN Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, TRHC is priced at $10.50, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas KERN's P/E ratio is -0.01. In terms of profitability, TRHC's ROE is +121.31%, compared to KERN's ROE of -2.22%. Regarding short-term risk, TRHC is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs MSPRZ Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MSPRZ has a market cap of 103.1K. Regarding current trading prices, TRHC is priced at $10.50, while MSPRZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, TRHC is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs LIFWW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, TRHC is priced at $10.50, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas LIFWW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, TRHC is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs CMAXW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, TRHC is priced at $10.50, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CMAXW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, TRHC is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs ACONW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, ACONW has a market cap of 18K. Regarding current trading prices, TRHC is priced at $10.50, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas ACONW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, TRHC is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs MSPRW Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MSPRW has a market cap of 6.3K. Regarding current trading prices, TRHC is priced at $10.50, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MSPRW's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, TRHC is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs UTRS Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, UTRS has a market cap of 888. Regarding current trading prices, TRHC is priced at $10.50, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas UTRS's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, TRHC is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs CERN Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CERN has a market cap of 0. Regarding current trading prices, TRHC is priced at $10.50, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CERN's P/E ratio is 55.84. In terms of profitability, TRHC's ROE is +121.31%, compared to CERN's ROE of +0.14%. Regarding short-term risk, TRHC is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for TRHC.
TRHC vs MSPRV Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, TRHC is priced at $10.50, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MSPRV's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to MSPRV's ROE of -3.08%. Regarding short-term risk, TRHC is less volatile compared to MSPRV. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs CNVY Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, TRHC is priced at $10.50, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas CNVY's P/E ratio is -71.50. In terms of profitability, TRHC's ROE is +121.31%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, TRHC is less volatile compared to CNVY. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.
TRHC vs MTBCP Comparison
TRHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRHC stands at 284M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, TRHC is priced at $10.50, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRHC currently has a P/E ratio of -4.27, whereas MTBCP's P/E ratio is N/A. In terms of profitability, TRHC's ROE is +121.31%, compared to MTBCP's ROE of +0.21%. Regarding short-term risk, TRHC is less volatile compared to MTBCP. This indicates potentially lower risk in terms of short-term price fluctuations for TRHC.